In The News
Lawyers for Banksia class action funder face possible court action
CIMIC settles shareholder class action for $45.25M
Boral wins challenge to CEO cross-examination in class actions
Hytera can’t dodge ‘substantial industrial theft’ finding in Motorola case
Barrister who accepted briefs for appearances on same day referred to watchdog
Judge approves $31.5M settlement in junior doctors class action
ASIC claims crypto firm Binance denied protections to derivatives investors
Melbourne law firm argues 700 clients can’t sue for negligence in class action
Aldi infringed copyright of Little Bellies fruit snacks, court finds
Hall & Wilcox brings on Moray & Agnew public law specialist
Please login to bookmarkClose

Global pharmaceutical firm Pfizer is mulling an application to stay a lawsuit by Merck Sharp & Dohme seeking to invalidate a patent related to the blockbuster Prevnar 13 vaccine as it awaits the outcome of similar proceedings in the US.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au